Bambusa Therapeutics IPO Raises $168.9M, Then Slips 6.3% in Nasdaq Debut

The Bambusa Therapeutics IPO raised $168.9 million, but the Seaport biotech’s shares closed their first day of trading below the offering price. The company sold 10,555,555 shares at $16 each on Oct. 29, and the stock, listed on the Nasdaq Global Select Market as BBTX, closed at $14.99 on Friday, Oct. 30, down 6.3%, Bloomberg Law reported. The offering is scheduled to close on Monday, Nov. 2.

$168.9M raised · $16.00 IPO price · $14.99 first-day close · $763.6M market value at the close

The deal: size, price and dates

Bambusa announced the pricing late on Oct. 29. According to the company’s release and its final prospectus filed with the U.S. Securities and Exchange Commission, all of the shares were sold by the company, and the underwriters have 30 days to buy up to 1,583,333 more shares at the same price. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor ran the books.

The deal grew before it priced. MarketWatch reported that Bambusa had planned to sell about 9.4 million shares at $15 to $17 each, and that it ended up selling nearly 10.6 million shares at the $16 midpoint. That is roughly 12% more shares than planned (TBR calculation). The Boston Business Journal reported that Bambusa is the 11th Massachusetts biotech to go public in 2026.

We first covered the company when it filed for its Nasdaq listing on Oct. 9. At that time, research firm Renaissance Capital reported a placeholder raise of up to $100 million, so the final deal came in about 69% above that figure (TBR calculation).

By the numbers: what the IPO pays for

The prospectus breaks the money down. Underwriting discounts and commissions come to $1.12 a share, or $11.8 million in total, which is 7% of the gross. After those fees and other offering expenses, Bambusa estimates net proceeds of about $152.4 million, or about $176.0 million if the underwriters buy all the extra shares.

The company plans to spend about $90 million on its lead drug, BBT001, including a planned Phase 2b study in atopic dermatitis (eczema), and about $40 million on BBT002, including a Phase 2b trial in a respiratory disease. That leaves about $22.4 million of the base net proceeds for its two preclinical programs and general corporate purposes (TBR calculation from the prospectus figures).

Bambusa had $71.5 million in cash, cash equivalents and marketable securities on June 30, 2026, according to the filing. It says the IPO money plus that cash should fund operations into late 2028. With 50,942,430 shares outstanding after the offering, the company was worth about $815 million at the $16 IPO price; at Friday’s close, Bloomberg Law put its market value at $763.6 million, a gap of roughly $51.5 million (TBR calculation). New investors also take immediate dilution of $11.73 a share, the prospectus says.

What Bambusa is developing

Founded in March 2024, Bambusa develops long-acting bispecific antibodies, single drugs designed to block two disease pathways at once, for immune and inflammatory diseases. Both lead programs were acquired from a BioNTech subsidiary in China, according to its filings. BBT001 targets IL-4Rα and IL-31 for eczema and chronic hives, and BBT002 targets IL-4Rα and IL-5 for respiratory diseases. Chief Executive Shanshan Xu previously led global external innovation at BioNTech, the Business Journal reported.

Our Take

This section is analysis and opinion, separate from the reporting above.

A first-day dip of about 6% is not a disaster, but it is a signal. Investors paid up for the size of the deal, then priced the stock lower once it traded, which suggests demand was strong enough to grow the offering but not strong enough to push it higher. For a company with no product revenue and early data from small trials, that is a reasonable outcome, and the cash runway into late 2028 removes the going-concern worry that hung over its filing.

The real test is the 12-week eczema data expected in the first half of 2027. Bambusa is chasing a market where Dupixent already dominates, so it has to show something clearly better, such as less frequent dosing. For Boston, another biotech listing is welcome after a hard year for the sector, marked by layoffs and empty lab space in Kendall Square and consolidation such as Flagship’s three-company merger. But with a small office headquarters, the listing adds capital more than local jobs for now.

What to watch next

The deal is set to close on Nov. 2. Watch whether the underwriters exercise their option for the extra 1.58 million shares, which would lift net proceeds to about $176 million, and whether the stock recovers the $16 offering price in its first weeks of trading.

Sources

• Bambusa Therapeutics: Announces pricing of upsized initial public offering (Oct. 29, 2026)
• SEC: Bambusa Therapeutics final prospectus (424B4)
• Bloomberg Law: Dermatology biotech Bambusa dips 6.3% after $168.9 million IPO
• MarketWatch: Bambusa Therapeutics upsized IPO priced at midpoint of views
• Boston Business Journal: Bambusa Therapeutics goes public after raising nearly $169M